stockportfolio.pro
Biohaven Ltd. (BHVN)
Healthcare · Biotechnology · NYSE
Biohaven Ltd. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-118.67M | $-213.80M | $-570.28M | $-408.17M | $-846.42M | $-738.82M |
| Net margin | — | — | — | — | — | — |
Source: Biohaven Ltd. SEC filings (10-K).
Explore 6 years of Biohaven Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BHVN in your portfolio →
Biohaven Ltd. financial history by metric
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Biohaven Ltd. — frequently asked questions
What is Biohaven Ltd.'s revenue?
Biohaven Ltd. (BHVN) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Biohaven Ltd. profitable?
No — BHVN reported a net loss of $-738.82M in fiscal 2025.
What is BHVN's P/E ratio?
Biohaven Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Biohaven Ltd. have?
As of fiscal year 2025, BHVN carried roughly $238.90M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Biohaven Ltd.'s market cap?
Biohaven Ltd. (BHVN) has a market capitalization of about $1.69B, based on the latest data in our nightly-refreshed cache.
When does Biohaven Ltd.'s fiscal year end?
BHVN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Biohaven Ltd.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.